arbekacin

structure given in first source

Also Known As:

1-N-((S)-4-amino-2-hydroxybutyryl)dibekacin; 4-amino-2-hydroxybutylyldibekacin; ME1100; arbekacin sulfate; habekacin; Butanamide, 4-amino-N-((1R,2S,3S,4R,5S)-5-amino-2-((3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy)-4-((2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranosyl)oxy)-3-hydroxycyclohexyl)-2-hydroxy-, (2S)-

Networked: 112 relevant articles (15 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Kanamycin: 1065
      - Dibekacin: 67
        arbekacin: 112

Experts

1.	Yanagihara, Katsunori: 3 articles (01/2017 - 04/2012)
2.	Mikamo, Hiroshige: 3 articles (07/2016 - 08/2012)
3.	Yamagishi, Yuka: 3 articles (07/2016 - 08/2012)
4.	Kariyama, R: 3 articles (04/2001 - 01/2000)
5.	Kumon, H: 3 articles (04/2001 - 01/2000)
6.	Ito, Yukako: 2 articles (06/2022 - 01/2021)
7.	Kobuchi, Shinji: 2 articles (06/2022 - 01/2021)
8.	Sakaeda, Toshiyuki: 2 articles (06/2022 - 01/2021)
9.	Sotozono, Chie: 2 articles (03/2022 - 10/2002)
10.	Ambrose, Paul G: 2 articles (01/2020 - 01/2019)

Related Diseases

1.	Infections 01/01/1994 - "A clinical investigation of methicillin-resistant Staphylococcus aureus (MRSA) infections to study the efficacy of arbekacin (ABK) was carried out by the MRSA Forum composed of 18 groups from 115 institutions in Japan. " 07/01/2016 - "The efficacy of arbekacin in patients with MRSA infections is influenced by the peak concentration (Cpeak)/MIC ratio (≧8). " 01/01/1994 - "Nationwide investigation in Japan on the efficacy of arbekacin in methicillin-resistant Staphylococcus aureus infections." 01/01/2021 - "Based on its pharmacokinetic characteristics in niche extravascular tissue spaces, arbekacin may be suitable for achieving sufficient clinical outcomes for MRSA infection because the drug is widely distributed in extracellular and intracellular compartments." 01/01/2017 - "The therapeutic effectiveness of arbekacin is directly related to C max at the infection site. "
2.	Endocarditis 12/01/2011 - "Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin." 12/01/2011 - "Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA." 09/01/2000 - "Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance." 12/01/2003 - "We adopted an in vitro infective endocarditis model (IVIEM) to compare the efficacy of vancomycin (VAN), arbekacin (ABK), and gentamicin (GEN) alone or in combination. " 12/01/2003 - "Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model."
3.	Sepsis (Septicemia) 02/01/2013 - "Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study." 09/01/2022 - "Arbekacin (ABK) is used to treat pneumonia and sepsis caused by methicillin-resistant Staphylococcus aureus, and therapeutic drug monitoring (TDM) is recommended. " 01/01/2014 - "ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. " 06/01/1994 - "Availability of arbekacin (ABK) was analyzed in the chemotherapy of 24 MRSA-infected patients with symptoms of pneumonia (12), sepsis (6) and others (6). " 08/01/2009 - "Although the MRSA-sepsis initially improved with arbekacin sulfate (ABK) administration, a high fever recurred with left thigh pain despite recovery of the neutrophil count after ABK was stopped. "
4.	Body Weight (Weight, Body) 12/01/1997 - "Arbekacin (ABK) was given at a dose of 2 mg/kg of body weight to 10 HD patients infected with methicillin-resistant Staphylococcus aureus (MRSA) for 2 weeks (six sessions in total), resulting in the complete disappearance of MRSA in 5 patients. " 07/01/1993 - "An allometric relationship was obtained between total body clearance of arbekacin, a novel aminoglycoside antibiotic, and animal body weight. " 04/01/2006 - "The investigated antimicrobial regimens were 100 mg arbekacin every 12 h (q12h), 6 mg daptomycin per kg of body weight/day, 600 mg linezolid q12h, and 100 mg tigecycline q24h alone and in combination (daptomycin, linezolid, and tigecycline) with arbekacin. " 01/01/2005 - "Human pharmacokinetic regimen simulations were as follows: cefepime, 2 g every 8 h (q8h) (C8) and 12 h (C12), continuous-infusion 2-g loading dose followed by 4 g alone or in combination with gentamicin and tobramycin (1.0 or 2.0 [G1 and G2 or TB1 and TB2] mg/kg of body weight q12h and 5.0 [G5 or TB5] mg/kg q24h), arbekacin (ARB) (100 mg q12h), linezolid (LIN) (600 mg q12h), tigecycline (TIG) (100 mg q24h), or daptomycin (DAP) (6 mg/kg q24h) for 48 h. "
5.	Staphylococcal Infections 06/01/2003 - "Efficacy and safety of arbekacin for staphylococcal infection in the NICU." 08/01/2007 - "Arbekacin may be a useful alternative to glycopeptides for the treatment of monomicrobial methicillin-resistant staphylococcal infections, as well as mixed infections with gram-negative bacilli, as most isolates of E. " 06/01/2003 - "This is a retrospective study on the efficacy and safety of arbekacin (ABK), an aminoglycoside antibiotic, for acquired staphylococcal infection in the neonatal intensive care nursery. " 06/01/2004 - "Arbekacin and linezolid are two new antibiotics that appear to be effective in the treatment of coagulase-negative staphylococcal infections, but their precise role has not yet been identified. "

Related Drugs and Biologics

1.	Vancomycin
2.	Anti-Bacterial Agents (Antibiotics)
3.	Aminoglycosides
4.	Ampicillin (Omnipen)
5.	Gentamicins (Gentamicin)
6.	Coagulase
7.	Linezolid (Zyvox)
8.	Teicoplanin
9.	Ofloxacin (Ofloxacine)
10.	Imipenem Drug Combination Cilastatin (Primaxin)

Related Therapies and Procedures

1.	Therapeutics
2.	Debridement
3.	Drug Therapy (Chemotherapy)
4.	Mechanical Ventilators (Ventilator)
5.	Combination Drug Therapy (Combination Chemotherapy)